ESCMID Online Lecture Library. by author
|
|
- Sophie Matthews
- 5 years ago
- Views:
Transcription
1 Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain
2 DISCLOSURES I have no potential conflicts with this presentation.
3 At the end of this presentation you WILL BE ABLE: TO remember the epidemiology, diagnosis and treatment of immunodepressed patients with Tuberculosis (TB), particularly in solid organ transplants recipients. TO learn the differences between TB infection and disease. TO understand how to prevent TB in immunodepressed patients. Learning objectives
4 Index 1. Introduction 2. Immunodepressed patients at risk of TB 3. How to Prevent TB in Immunosuppressed patients? A. Rule out active TB B. Diagnosis of TB infection/latent TB infection (LTBI) C. Identify people at risk D. Treatment of LTBI E. Vaccines
5 (TB) Transmitted from person to person via droplets from the throat and lungs of people with the active respiratory disease!!!. Infectious bacterial disease caused by Mycobacterium tuberculosis that most commonly affects the lungs.
6 Mycobacterium tuberculosis First discovered in 1882 by Robert Koch -Zhiel-Neelsen stain or acid-fast stain
7 Estimated TB incidence rates 2014
8 WHO we find ourselves at a crossroad in the fight against tuberculosis. Data reported by over 200 countries that account for more than 99% of the world s TB cases TB still remains one of the major world health challenges.
9 2. Who are we thinking about when we speak of immunosuppressed patients at risk for TB? General aspects of TB
10 HIV patients Patients with immunosuppressive therapy : biological therapy.. Patients with end-stage kidney disease Solid Organ Transplants recipients Stem Cell Transplants recipients Other types of patients: Diabetes, Tobacco??.
11 HIV Patients Condition Immunosuppressive therapy (biological therapy) End-stage kidney disease Solid organ transplant Stem cell Transplant Risk of Tuberculosis in immunosuppressed patients TB risk times greater than among those without HIV 25 times more than immunocompetent 6-25 times more than immunocompetent times more than immunocompetent 2 times more than immunocompetent
12
13 Patients treated with anti-tnfα agents such infliximab, etanercept, adalimumab, certolizumab pegol and golimumab, have 1.6 to 25.1 times higher risk of tuberculosis. Within the anti-tnf agents the lowest risk of tuberculosis is associated with etanercept. Infliximab has 3 times higher risk of developing tuberculosis than etanercept.
14 Dialysis patients had a 3.62-fold increase in TB rate 12 eligible studies were identified with end-stage renal disease patients and 560 TB cases.
15 Tuberculosis in SOT recipients 1. Lopez de Castilla and Schluger, Transplant Infect Dis 2010; 12: Canet et al. Nephrol Dial Transplant Garcia-Goez et al. Transplantation Proc 2009; 41: Torre-Cisneros et al. Clin Infect Dis 2009; 48:
16 CID 2009:48 (15 June) Incidence of TB in SOT (RESITRA Cohort)
17 Timing of tuberculosis following SOT López de Castilla and Schluger, Transplant Infect Dis 2010; 12:
18 20 confirmed cases were found among 8013 patients (8 in 5147 autologous and 12 in 2866 allogeneic SCT). Compared with the general population, TB was more frequent after allogeneic (RR 2.95) but not after autologous SCT. Transplant type Incidence (95% CI) Autologous 71 (22-120) Allogeneic 136 (59-212) All 101 (57-145) RR (95% CI) 1.72 ( ) 2.95 ( ) 2.21 ( )
19 TB after SCT is a late infection (median 324 days post transplant), predominately affects the lungs (80% of the cases), appears to respond well to treatment but has a high mortality (25%) in allogeneic recipients Int J Tuberc Lung Dis 2015; 19 (1):58-64
20 3. How to Prevent TB in Immunodepressed patients?
21 A. Rule out active TB disease Evaluation for TB 1. Medical history : Past TB, Background TB endemicity, Current TB contact, Clinical Symptoms (Productive prolonged cough, Hemoptysis, Fever and chills, Night sweats, Fatigue, Loss of appetite, Weight loss ) 2. Physical examination 3. Chest x-ray: by itself, cannot confirm the diagnosis of TB but can be used in conjunction with other diagnostic indicators 4. Bacteriologic exam: Sputum smear and culture 5. Diagnosis of TB infection: Tuberculin skin test (TST) Interferon-gamma release assays (IGRAs)
22 B. Diagnosis of TB infection Tuberculin Skin Test (TST) Intradermal injection of PPD-S (Seibert s purified protein derivative), or the PPD-RT23. Interferon-Gamma Release Assays (IGRAs) IGRAs: detect interferon-gamma (IFN-) release by sensitized T cells after stimulation with specific M. tuberculosis antigens (earlysecreted antigenic target protein (ESAT-6); filtrate protein (CFP-10). QuantiFERON-TB Gold assay (QFT-G) and the T-SPOT QFT-G in-tube version (QFT-GIT) includes a third antigen, TB7.7
23 In infected individuals, both TST and IGRAs detect the presence of Mtb specific T-cell responses. Intradermal injection of PPD Ag presenting cell Ag MTC Central memory T cells Effector memory T cells TNFα IFNγ IL8 Neither of them can distinguish active disease from latent infection (LTBI) Induration Detection of in vitro IFNγ
24 TST IGRAs C. Diagnosis of Latent TB infection (LTBI) LTBI: presence of immune responses to previously acquired Mtb infection, without clinical evidence of active TB. A gold standard for the diagnosis of the LTBI is lacking. Low specificity : Contains a mixture of more than 200 antigens that are shared by mycobacteria other than Mtb, and includes the vaccine strain of M. bovis bacillus Calmette-Guerin (BCG). Higher specificity in low-tb-prevalence areas and less crossactivity with the BCG vaccine in non-hiv-infected persons
25 Remember LTBI LTBI vs. TB Disease Tubercle bacilli in the body TB Disease TST or IGRAs result usually positive Chest x-ray usually normal Sputum smears and cultures negative No symptoms Not infectious Not a case of TB Chest x-ray usually abnormal Smears and cultures positive Symptoms such as cough, fever, weight loss Often infectious before treatment A case of TB 25
26
27 HIV patients Biological RX
28 SOT and SCT patients
29 Summary of the recommendations for different clinical settings
30 AIM. To compare the performance of TST and IGRAs and evaluated their ability to identify those at risk for development of TB. TUBERCULOSIS median follow-up 1.8 y. IComp (n = 211) HIV (n = 768) CRF (n = 270) June 1, 2008 to May 31, centers/11 European Countries 1537 immunocompromised patients 211 immunocompetent control subjects RA (n = 199) SOT (n = 197) 10 1 Negative tests 5 1 Am J Respir Crit Care Med, 2014 SCT (n = 103) Progression toward TB was highest in HIV infected individuals and was poorly predicted by TST or IGRAs..
31 Cross-Sectional Study: Between-Test Agreement and Association with Exposure to Mtb: -HIV: Moderate associations of + IGRA. -SOT: a positive ELISA was significantly associated. -RA: A significant association of each of the three tests. -CRF: the percentage of positive test results to RA, not association. It is unclear which test should be preferred for immunodiagnostic testing Am J Respir Crit Care Med, 2014
32 Implications of Latent Tuberculosis Infection (LTBI) Testing for progression towards TB 1-2 y 1-2 y When using a management strategy relying on universal screening, preventive chemotherapy is more effective when combined with assessment of additional TB-related risk factors. Sester M, Bumbacea D, Duarte R, Lange C. Tuberculosis in the immunocompromised host. Eur Respir Monogr 2012;58:
33 TB Risk Relative risk of TB compared to the general population WHO s recommendation for screening and treatment for LTBI Country A: countries with an estimated TB incidence less than 100/100,000 Population Country B: For resource-limited countries that do not belong to country A. Emerg Microb Infecti (2016) 5, e10; doi: /emi
34 Screening and treat LTBI before transplant?
35 Which should be done in practice? Is screening for LTBI recommended for all transplants patients? High incidence of TB (>100/ ) (South Africa): Treat without screening. Medium incidence: Screen and treat positives. Low incidence (<20/ ): Screen if one or more risk factors are present and treat positives. Eur Respir J 2012; 40:
36
37 Will be in this paper the feature of LTBI diagnosis? -Blood from adolescents in South Africa every 6 months for 2 years and monitored the adolescents for progression of TB disease. - A prospective signature of risk was derived from whole blood RNA sequencing data by comparing participants who developed active TB disease (progressors) with those who remained healthy (matched controls). The whole blood TB risk signature prospectively identified people at risk of developing active TB, opening the possibility for targeted intervention to prevent the disease
38 D. Treatment of LTBI Well now we know how to identify patients for preventive therapy (that is not the same as patients with an actual risk of progression!!). Daily Isoniazid (INH) therapy for months are still considered the standard of care for preventive therapy? Alternative therapies?
39 World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: WHO, Available at daily daily daily daily weekly WHO-recommended preventive regimens for LTBI
40 Treatment of latent TB infection (LTBI) is increasingly advocated in persons with HIV co-infection Daily self-administered INH 300 mg for 9 months (9H) or daily rifampin 600 mg for 4 months (4R).Isoniazid is the clear preference for treating LTBI in a patient on drugs that have unfavorable interactions with rifamycins. Rifabutin should be used for LTBI only if there is a compelling need for short-course treatment of LTBI, and/or if neither 9H nor 4R can be used. Recently a new regimen of 12 once-weekly doses of isoniazid 900 mg plus rifapentine 900 mg administered as directly observed therapy (DOT) has been recommended for use in persons who are HIV-uninfected or in persons with HIV who are otherwise healthy and not receiving ART.
41 INH administration at the dose of 5 mg/kg, along with pyridoxine for 6-9 months. Only once. Monitor liver function tests in monthly intervals. In exceptional cases RMP at the dose of 10 mg/kg for 4 months (neurotoxicity of INH, INH-resistant strain) or a combination of RMP + INH daily for 3 months.
42 daily European survey on the management of TB in SOT recipients and candidates (ESCMID Study Group of Infection in Compromised Hosts (ESGICH) Most centers (73%) initiated treatment of LTBI prior to transplantation in non-liver transplant candidates, but only 38% of centers did so in liver transplant patients. Transplant International Volume 26, Issue 8, pages e69-e70, 15 APR 2013 DOI: /tri
43 CID 2015;60(11):1642 9
44 Transplantation Jan 27;97(2): patients INH/RPT x 12 weeks No discontinuation due to hepatotoxicity Tx F-up HPTx Discontinuation Liver (n= 7) Kidney (n= 8) Heart (n= 2) m None 1 (Change hospice care) m None 3 (HT crisis, nausea/vomiting, lost insurance coverage) 6.6 & 7.2 m None None
45 TB Vaccines Until a new vaccine is proven more effective and safe than BCG, BCG should remain part of the immunization schedules for neonates and children at risk for TB as a fundamental prophylactic measure.
46 Messages TB is a major complication in immunosuppressed patients. Patients with high-risk factors for TB reactivation should undergo screening and treatment for LTBI. IGRAs and the TST are both used to screen for LTBI, and although some studies in low-tb-prevalence areas reported a higher specificity with IGRAs than with the TST, neither method had a satisfying predictive value for active TB.
47 Messages At present, the WHO recommends five prophylactic regimens 6INH, 9INH, 3-4RIF, 3-4RIF+ INH and 3RPT + INH none of which has shown superiority over the conventional 6INH or 9INH therapies. The 3-4RIF and 3RPT +INH regimens have been reported to have fewer hepatotoxicity events, but the quality of evidence is low. For high-risk groups, INH monotherapy could reduce the TB risk in HIV-infected patients and transplant recipients, but for others, little evidence is available to draw a conclusion at this time.
48
PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationTuberculosis (TB) Fundamentals for School Nurses
Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationScreening and Treatment Recommendations for Persons Exposed to MDR TB
Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED
Tuberculosis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments COL Paul Keiser LTC James E. Moon LTC Jaime Mancuso LTC Anjali Kunz MAJ Kristopher Paolino MAJ Leyi
More informationAdvanced Concepts in Pediatric Tuberculosis
Advanced Concepts in Pediatric Tuberculosis: Nizar F. Maraqa, MD, FPIDS Division of Pediatric Infectious Diseases & Immunology University of Florida College of Medicine - Jacksonville Advanced Concepts
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationCoordinating with Public Health on Tuberculosis Testing & Treatment
Coordinating with Public Health on Tuberculosis Testing & Treatment Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Associate Professor University of New Mexico College of Pharmacy Objectives 1. Identify
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationAdvanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014
Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationLatent Tuberculosis in Adults: From Testing TO Treatment
Latent Tuberculosis in Adults: From Testing TO Treatment Sergio M. Borgia, MD, MSc., FRCP(C) Infectious Diseases Consultant, WOHS Medical Director, WOHS Tuberculosis Clinic Assistant Clinical Professor,
More informationATS/CDC Guidelines for Treating Latent TB Infection
TB Intensive Tyler, Texas June 2-4, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy R. Aksamit, MD June 2, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis Intensive University of
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationTB Intensive San Antonio, Texas August 7-10, 2012
TB Intensive San Antonio, Texas August 7-10, 2012 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD August 7, 2012 Timothy Aksamit, MD has the following disclosures to make: No conflict
More informationTB Intensive. San San Antonio, Texas. December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD; Mayo Clinic December 1, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2, 2011 ATS/CDC Guidelines for Treating LTBI Timothy Aksamit, MD April 6, 2011 Timothy Aksamit, MD has the following disclosures to make: No conflict of interests
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationTuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director
Tuberculosis What you need to know James Zoretic M.D., M.P.H. Regions 2 and 3 Director What is Tuberculosis? Tuberculosis, (TB) is a communicable disease caused by the Mycobacterium tuberculosis bacillus
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lynn Horvath, MD November 11, 2014 Lynn Horvath, MD has the following disclosures to
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTuberculosis Infection in the US Military
Tuberculosis Infection in the US Military Edward Munch. The Sick Child. (1885) Anjali Kunz, MAJ (P), MC Pediatric Infectious Disease, Chief, JBLM Courtesy of : Paul B. Keiser, Feb 2014 Walter Reed Army
More informationSummary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationGuidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
More informationTuberculosis Education for the Medical Professional
Tuberculosis Education for the Medical Professional North Dakota Diagnosis and Medical Management of Latent TB Infection Dawn Farrell, RN, BSN, PHN Maria Robles, BSN July 10, 2007 Tuberculosis Education
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationTB Nurse Case Management San Antonio, Texas March 7 9, Clinical Diagnosis and
TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Clinical Diagnosis and Management of LTBI Lynn Horvath, MD March 7, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationTB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION
TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationTB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014
TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationManagement of Pediatric Tuberculosis in New Jersey
Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationOngoing Research on LTBI and Research priorities in India
Ongoing Research on LTBI and Research priorities in India Dr. C.Padmapriyadarsini, MD, MS ICMR-National Institute for Research in Tuberculosis Chennai, India Technical Consultation Meeting on Programmatic
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationChallenges in Management: Solid Organ Transplantation & Tuberculosis
Challenges in Management: Solid Organ Transplantation & Tuberculosis Michele I Morris, M.D., FACP, FIDSA Director, Immunocompromised Host Section Associate Professor of Clinical Medicine Division of Infectious
More informationUC DavisTB Screening Requirement: How to submit your TB Health Assessment Form
UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form Step 1 If after completing the TB Risk Screening you are found to be at high risk, you must complete the Tuberculosis (TB)
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Tuberculosis Pathogenesis and Treatment f Latent TB Infection Lynn Horvath, MD October 15, 2013 Lynn Horvath, MD has the following disclosures to make: No
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationMichael J. Huey, MD. NYSCHA Annual Meeting WE-2, October 19, 2016
Michael J. Huey, MD Assistant Vice President and Executive Director Emory University Student Health Services Associate Professor, Family and Preventive Medicine Emory University School of Medicine President-elect
More informationRevised Technical Instructions for Civil Surgeons. October 9, 2018
Revised Technical Instructions for Civil Surgeons October 9, 2018 Speakers Joanna Regan Centers for Disease Control and Prevention Shereen Katrak California Department of Public Health Pennan Barry California
More informationLatent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or
More informationTuberculosis in Children and Adolescents 2017
Tuberculosis in Children and Adolescents 2017 George D. McSherry, MD Division of Infectious Diseases Penn State Children s Hospital and Pediatric Section Northeastern Regional Training and Medical Consultation
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 6 Tuberculosis. TEXT ASSIGNMENT Paragraphs 6-1 through 6-11. LESSON OBJECTIVES After completing this lesson, you should be able to: 6-1. Identify the characteristics, signs/ symptoms,
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014
Guidelines to Revisions to the School Mandate and Requirements 1) What are the tuberculosis (TB) screening requirements for school entrance in Santa Clara County? Students must undergo a TB risk assessment
More information